|
1
|
Jovčevska I, Kočevar N and Komel R: Glioma
and glioblastoma - how much do we (not) know? Mol Clin Oncol.
1:935–941. 2013.
|
|
2
|
Bleeker FE, Molenaar RJ and Leenstra S:
Recent advances in the molecular understanding of glioblastoma. J
Neurooncol. 108:11–27. 2012.
|
|
3
|
Thomas A, Tanaka M, Trepel J, Reinhold WC,
Rajapakse VN and Pommier Y: Temozolomide in the era of precision
medicine. Cancer Res. 77:823–826. 2017.
|
|
4
|
Perry J, Laperriere N, Zuraw L, Chambers
A, Spithoff K and Cairncross JG; Neuro-oncology Disease Site Group;
Cancer Care Ontario Program in Evidence-Based Care: Adjuvant
chemotherapy for adults with malignant glioma: A systematic review.
Can J Neurol Sci. 34:402–410. 2007.
|
|
5
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005.
|
|
6
|
Kitange GJ, Carlson BL, Schroeder MA,
Grogan PT, Lamont JD, Decker PA, Wu W, James CD and Sarkaria JN:
Induction of MGMT expression is associated with temozolomide
resistance in glioblastoma xenografts. Neuro-oncol. 11:281–291.
2009.
|
|
7
|
Qiu ZK, Shen D, Chen YS, Yang QY, Guo CC,
Feng BH and Chen ZP: Enhanced MGMT expression contributes to
temozolomide resistance in glioma stem-like cells. Chin J Cancer.
33:115–122. 2014.
|
|
8
|
Hegi ME, Diserens AC, Gorlia T, Hamou MF,
de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani
L, et al: MGMT gene silencing and benefit from temozolomide in
glioblastoma. N Engl J Med. 352:997–1003. 2005.
|
|
9
|
Kondo N, Takahashi A, Ono K and Ohnishi T:
DNA damage induced by alkylating agents and repair pathways. J
Nucleic Acids. 2010:5435312010.
|
|
10
|
Aldana-Masangkay GI and Sakamoto KM: The
role of HDAC6 in cancer. J Biomed Biotechnol. 2011:8758242011.
|
|
11
|
Seidel C, Schnekenburger M, Dicato M and
Diederich M: Histone deacetylase 6 in health and disease.
Epigenomics. 7:103–118. 2015.
|
|
12
|
Smith Q, Macklin B, Chan XY, Jones H,
Trempel M, Yoder MC and Gerecht S: Differential HDAC6 activity
modulates ciliogenesis and subsequent mechanosensing of endothelial
cells derived from pluripotent stem cells. Cell Rep. 24:895–908.e6.
2018.
|
|
13
|
Li S, Liu X, Chen X, Zhang L and Wang X:
Histone deacetylase 6 promotes growth of glioblastoma through
inhibition of SMAD2 signaling. Tumour Biol. 36:9661–9665. 2015.
|
|
14
|
Moser JJ, Fritzler MJ and Rattner JB:
Primary ciliogenesis defects are associated with human
astrocytoma/glioblastoma cells. BMC Cancer. 9:4482009.
|
|
15
|
Wang Z, Hu P, Tang F, Lian H, Chen X,
Zhang Y, He X, Liu W and Xie C: HDAC6 promotes cell proliferation
and confers resistance to temozolomide in glioblastoma. Cancer
Lett. 379:134–142. 2016.
|
|
16
|
Corbit KC, Aanstad P, Singla V, Norman AR,
Stainier DY and Reiter JF: Vertebrate Smoothened functions at the
primary cilium. Nature. 437:1018–1021. 2005.
|
|
17
|
Haycraft CJ, Banizs B, Aydin-Son Y, Zhang
Q, Michaud EJ and Yoder BK: Gli2 and Gli3 localize to cilia and
require the intraflagellar transport protein polaris for processing
and function. PLoS Genet. 1:e532005.
|
|
18
|
Simons M, Gloy J, Ganner A, Bullerkotte A,
Bashkurov M, Krönig C, Schermer B, Benzing T, Cabello OA, Jenny A,
et al: Inversin, the gene product mutated in nephronophthisis type
II, functions as a molecular switch between Wnt signaling pathways.
Nat Genet. 37:537–543. 2005.
|
|
19
|
Goetz SC and Anderson KV: The primary
cilium: A signalling centre during vertebrate development. Nat Rev
Genet. 11:331–344. 2010.
|
|
20
|
Braun S, Oppermann H, Mueller A, Renner C,
Hovhannisyan A, Baran-Schmidt R, Gebhardt R, Hipkiss A, Thiery J,
Meixensberger J, et al: Hedgehog signaling in glioblastoma
multiforme. Cancer Biol Ther. 13:487–495. 2012.
|
|
21
|
Hassounah NB, Bunch TA and McDermott KM:
Molecular pathways: The role of primary cilia in cancer progression
and therapeutics with a focus on Hedgehog signaling. Clin Cancer
Res. 18:2429–2435. 2012.
|
|
22
|
Pasca di Magliano M and Hebrok M: Hedgehog
signalling in cancer formation and maintenance. Nat Rev Cancer.
3:903–911. 2003.
|
|
23
|
Liu YJ, Ma YC, Zhang WJ, Yang ZZ, Liang
DS, Wu ZF and Qi XR: Combination therapy with micellarized
cyclopamine and temozolomide attenuate glioblastoma growth through
Gli1 down-regulation. Oncotarget. 8:42495–42509. 2017.
|
|
24
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009.
|
|
25
|
Skrypek N, Goossens S, De Smedt E,
Vandamme N and Berx G: Epithelial-to-mesenchymal transition:
Epigenetic reprogramming driving cellular plasticity. Trends Genet.
33:943–959. 2017.
|
|
26
|
Zeisberg M and Neilson EG: Biomarkers for
epithelial-mesenchymal transitions. J Clin Invest. 119:1429–1437.
2009.
|
|
27
|
Ramos FS, Wons L, Cavalli IJ and Ribeiro
EMSF: Epithelial-mesenchymal transition in cancer: An overview.
Integr Cancer Sci Ther. 4:1–5. 2017.
|
|
28
|
Iwadate Y: Epithelial-mesenchymal
transition in glioblastoma progression. Oncol Lett. 11:1615–1620.
2016.
|
|
29
|
Kahlert UD, Maciaczyk D, Doostkam S, Orr
BA, Simons B, Bogiel T, Reithmeier T, Prinz M, Schubert J,
Niedermann G, et al: Activation of canonical WNT/β-catenin
signaling enhances in vitro motility of glioblastoma cells by
activation of ZEB1 and other activators of
epithelial-to-mesenchymal transition. Cancer Lett. 325:42–53.
2012.
|
|
30
|
Xu L, Liu N, Gu H, Wang H, Shi Y, Ma X, Ma
S, Ni J, Tao M, Qiu A, et al: Histone deacetylase 6 inhibition
counteracts the epithelial-mesenchymal transition of peritoneal
mesothelial cells and prevents peritoneal fibrosis. Oncotarget.
8:88730–88750. 2017.
|
|
31
|
Dunigan DD, Waters SB and Owen TC: Aqueous
soluble tetrazolium/formazan MTS as an indicator of NADH- and
NADPH-dependent dehydrogenase activity. Biotechniques. 19:640–649.
1995.
|
|
32
|
Geissmann Q: OpenCFU, a new free and
open-source software to count cell colonies and other circular
objects. PLoS One. 8:e540722013.
|
|
33
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008.
|
|
34
|
Urdiciain A, Meléndez B, Rey JA, Idoate MA
and Castresana JS: Panobinostat potentiates temozolomide effects
and reverses epithelial–mesenchymal transition in glioblastoma
cells. Epigenomes. 2:52018.
|
|
35
|
Yang W, Liu Y, Gao R, Yu H and Sun T:
HDAC6 inhibition induces glioma stem cells differentiation and
enhances cellular radiation sensitivity through the SHH/Gli1
signaling pathway. Cancer Lett. 415:164–176. 2018.
|
|
36
|
Gradilone SA, Radtke BN, Bogert PS, Huang
BQ, Gajdos GB and LaRusso NF: HDAC6 inhibition restores ciliary
expression and decreases tumor growth. Cancer Res. 73:2259–2270.
2013.
|
|
37
|
Han SP, Kim JH, Han ME, Sim HE, Kim KS,
Yoon S, Baek SY, Kim BS and Oh SO: SNAI1 is involved in the
proliferation and migration of glioblastoma cells. Cell Mol
Neurobiol. 31:489–496. 2011.
|
|
38
|
Myung JK, Choi SA, Kim SK, Wang KC and
Park SH: Snail plays an oncogenic role in glioblastoma by promoting
epithelial mesenchymal transition. Int J Clin Exp Pathol.
7:1977–1987. 2014.
|
|
39
|
Stepanenko AA, Andreieva SV, Korets KV,
Mykytenko DO, Baklaushev VP, Huleyuk NL, Kovalova OA, Kotsarenko
KV, Chekhonin VP, Vassetzky YS, et al: Temozolomide promotes
genomic and phenotypic changes in glioblastoma cells. Cancer Cell
Int. 16:362016.
|
|
40
|
Gu S, Liu Y, Zhu B, Ding K, Yao TP, Chen
F, Zhan L, Xu P, Ehrlich M, Liang T, et al: Loss of α-tubulin
acetylation is associated with TGF-β-induced epithelial-mesenchymal
transition. J Biol Chem. 291:5396–5405. 2016.
|
|
41
|
Dong J, Zheng N, Wang X, Tang C, Yan P,
Zhou HB and Huang J: A novel HDAC6 inhibitor exerts an anti-cancer
effect by triggering cell cycle arrest and apoptosis in gastric
cancer. Eur J Pharmacol. 828:67–79. 2018.
|
|
42
|
Li ZY, Zhang C, Zhang Y, Chen L, Chen BD,
Li QZ, Zhang XJ and Li WP: A novel HDAC6 inhibitor Tubastatin A:
Controls HDAC6-p97/VCP-mediated ubiquitination-autophagy turnover
and reverses Temozolomide-induced ER stress-tolerance in GBM cells.
Cancer Lett. 391:89–99. 2017.
|
|
43
|
Ryu HW, Shin DH, Lee DH, Choi J, Han G,
Lee KY and Kwon SH: HDAC6 deacetylates p53 at lysines 381/382 and
differentially coordinates p53-induced apoptosis. Cancer Lett.
391:162–171. 2017.
|
|
44
|
Sarkisian MR, Siebzehnrubl D, Hoang-Minh
L, Deleyrolle L, Silver DJ, Siebzehnrubl FA, Guadiana SM,
Srivinasan G, Semple-Rowland S, Harrison JK, et al: Detection of
primary cilia in human glioblastoma. J Neurooncol. 117:15–24.
2014.
|
|
45
|
Menzl I, Lebeau L, Pandey R, Hassounah NB,
Li FW, Nagle R, Weihs K and McDermott KM: Loss of primary cilia
occurs early in breast cancer development. Cilia. 3:72014.
|
|
46
|
Kim J, Dabiri S and Seeley ES: Primary
cilium depletion typifies cutaneous melanoma in situ and malignant
melanoma. PLoS One. 6:e274102011.
|
|
47
|
Schraml P, Frew IJ, Thoma CR, Boysen G,
Struckmann K, Krek W and Moch H: Sporadic clear cell renal cell
carcinoma but not the papillary type is characterized by severely
reduced frequency of primary cilia. Mod Pathol. 22:31–36. 2009.
|
|
48
|
Liu Z, Rebowe RE, Wang Z, Li Y, Wang Z,
DePaolo JS, Guo J, Qian C and Liu W: KIF3a promotes proliferation
and invasion via Wnt signaling in advanced prostate cancer. Mol
Cancer Res. 12:491–503. 2014.
|
|
49
|
Kim M, Suh YA, Oh JH, Lee BR, Kim J and
Jang SJ: KIF3A binds to β-arrestin for suppressing Wnt/β-catenin
signalling independently of primary cilia in lung cancer. Sci Rep.
6:327702016.
|
|
50
|
Emoto K, Masugi Y, Yamazaki K, Effendi K,
Tsujikawa H, Tanabe M, Kitagawa Y and Sakamoto M: Presence of
primary cilia in cancer cells correlates with prognosis of
pancreatic ductal adenocarcinoma. Hum Pathol. 45:817–825. 2014.
|
|
51
|
Barakat MT, Humke EW and Scott MP: Kif3a
is necessary for initiation and maintenance of medulloblastoma.
Carcinogenesis. 34:1382–1392. 2013.
|
|
52
|
Lai SW, Huang BR, Liu YS, Lin HY, Chen CC,
Tsai CF, Lu DY and Lin C: Differential characterization of
temozolomide-resistant human glioma cells. Int J Mol Sci.
19:1272018.
|
